NMI 221

Drug Profile

NMI 221

Alternative Names: Moxisylyte-SNO; S-Nitrosylated moxisylyte; SNO-moxisylyte

Latest Information Update: 19 Mar 2008

Price : $50

At a glance

  • Originator NitroMed
  • Developer Boston University School of Medicine; NitroMed
  • Class Nitroso compounds; Small molecules
  • Mechanism of Action Alpha adrenergic receptor antagonists; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Erectile dysfunction

Most Recent Events

  • 06 Mar 2008 NitroMed's nitric oxide-enhancing technologies are available for licensing
  • 22 Oct 1999 A preclinical study has been added to the adverse events and pharmacodynamics sections
  • 28 Sep 1999 Preclinical development for Erectile dysfunction in USA (Transurethral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top